Dragging Ras Back in the Ring

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

ras GENES

Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D. B., Tolcher, A. W., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,541

A Comprehensive Survey of Ras Mutations in Cancer

Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism

Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043

GEFs and GAPs: Critical Elements in the Control of Small G Proteins

Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903

Ras oncogenes: split personalities

Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467

A Cytoplasmic Protein Stimulates Normal N- ras p21 GTPase, But Does Not Affect Oncogenic Mutants

Trahey, M., & McCormick, F. (1987) · Science · doi:10.1126/science.2821624 · Cited by 1,211

Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Abou‐Alfa, G. K., Schwartz, L. H., Ricci, S., Amadori, D., Santoro, A., Figer, A., Grève, J. D., Douillard, J., Lathia, C. D., Schwartz, B. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195

A New Strategy to Control and Eradicate “Undruggable” Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology

Sciver, R. E. V., Lee, M., Lee, C. G. L., Lafever, A., Svyatova, E. A., Kanda, K., Collier, A. L., van Reesema, L. L. S., Tang-Tan, A. M., Zheleva, V. P., et al. (2018) · Cancers · doi:10.3390/cancers10050142 · Cited by 21

Bioreducible, arginine-rich polydisulfide-based siRNA nanocomplexes with excellent tumor penetration for efficient gene silencing

Zhang, X., Hong, K., Sun, Q., Zhu, Y., & Du, J. (2021) · Biomaterials Science · doi:10.1039/d1bm00643f · Cited by 22

Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein

Tripathi, B. K., Anderman, M. F., Bhargava, D., Boccuzzi, L., Qian, X., Wang, D., Durkin, M. E., Papageorge, A. G., de Miguel, F. J., Politi, K. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26993-3 · Cited by 22

Recent advances in the biology and therapy of medullary thyroid carcinoma

Nelkin, B. D. (2017) · F1000Research · doi:10.12688/f1000research.12645.1 · Cited by 21

Clinical update on K-Ras targeted therapy in gastrointestinal cancers

Pant, S., Hubbard, J. M., Martinelli, E., & Bekaii‐Saab, T. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.011 · Cited by 21

Oncogenic Ras mutant causes the hyperactivation of NF‐κB via acceleration of its transcriptional activation

Tago, K., Funakoshi‐Tago, M., Ohta, S., Kawata, H., Saitoh, H., Horie, H., Aoki‐Ohmura, C., Yamauchi, J., Tanaka, A., Matsugi, J., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12580 · Cited by 22

KRAS Ubiquitination at Lysine 104 Retains Exchange Factor Regulation by Dynamically Modulating the Conformation of the Interface

Yin, G., Zhang, J., Nair, V. V., Truong, V. H., Chaia, A. I., Petela, J., Harrison, J. S., Gorfe, A. A., & Campbell, S. L. (2020) · iScience · doi:10.1016/j.isci.2020.101448 · Cited by 21

Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma

Nakamoto-Matsubara, R., Nardi, V., Horick, N., Fukushima, T., Han, R. S., Shome, R., Ochi, K., Panaroni, C., Fulzele, K. S., Rexha, F., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01190-9 · Cited by 20

Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?

Krupa, K., Fudalej, M. M., Włoszek, E., Miski, H., Badowska-Kozakiewicz, A. M., Mękal, D., Budzik, M. P., Czerw, A. I., & Deptała, A. (2025) · Cancers · doi:10.3390/cancers17152453 · Cited by 21

Searching for the Chokehold of NRAS Mutant Melanoma

Posch, C., Vujic, I., Monshi, B., Sanlorenzo, M., Weihsengruber, F., Rappersberger, K., & Ortiz-Urda, S. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.03.006 · Cited by 19

Acute myeloid leukemia: Therapy resistance and a potential role for tetraspanin membrane scaffolds

Floren, M., & Gillette, J. M. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106029 · Cited by 20

The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?

Lv, J., Wang, J., Chang, S., Liu, M., & Pang, X. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv102 · Cited by 22

5‐Fluorouracil preferentially sensitizes mutant KRAS non‐small cell lung carcinoma cells to TRAIL‐induced apoptosis

Wang, H., Yang, T., & Wu, X. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.06.003 · Cited by 20

A High-Throughput Assay for Small Molecule Destabilizers of the KRAS Oncoprotein

Carver, J. O., Dexheimer, T. S., Hsu, D. J., Weng, M., Smith, J. L., Guha, R., Jadhav, A., Simeonov, A. M., & Luo, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103836 · Cited by 20

Classic Ras Proteins Promote Proliferation and Survival via Distinct Phosphoproteome Alterations in Neurofibromin-Null Malignant Peripheral Nerve Sheath Tumor Cells

Brossier, N. M., Prechtl, A. M., Longo, J. F., Barnes, S., Wilson, L. S., Byer, S. J., Brosius, S. N., & Carroll, S. L. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000201 · Cited by 20

CBP501 inhibits EGF-dependent cell migration, invasion and epithelial-to-mesenchymal transition of non-small cell lung cancer cells by blocking KRas to calmodulin binding

Saito, N., Mine, N., Kufe, D. W., Hoff, D. D. V., & Kawabe, T. (2017) · Oncotarget · doi:10.18632/oncotarget.18598 · Cited by 20

Engaging Anaphase Catastrophe Mechanisms to Eradicate Aneuploid Cancers

Kawakami, M., Mustachio, L. M., Liu, X., & Dmitrovsky, E. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1108 · Cited by 17

Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas

Sumi, T., Hirai, S., Yamaguchi, M., Tanaka, Y., Tada, M., Yamada, G., Hasegawa, T., Miyagi, Y., Niki, T., Watanabe, A., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4365 · Cited by 20

Second harmonic generation detection of Ras conformational changes and discovery of a small molecule binder

Donohue, E., Khorsand, S., Mercado, G., Varney, K. M., Wilder, P. T., Yu, W., MacKerell, A. D., Alexander, P., Van, Q. N., Moree, B., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905516116 · Cited by 20

Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer

Cho, Y. S., Kim, G. C., Lee, H. M., Kim, B., Kim, H. R., Chung, S. W., Chang, H. W., Ko, Y. G., Lee, Y. S., Kim, S. W., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.026 · Cited by 20

Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors

Stites, E. C., & Shaw, A. S. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12291 · Cited by 20

Molecular therapeutics in pancreas cancer

Narayanan, V., & Weekes, C. D. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i4.366 · Cited by 19

Epigenomic Inactivation of RasGAPs Activates RAS Signaling in a Subset of Luminal B Breast Cancers

Sears, R. C., & Gray, J. W. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1423 · Cited by 19

The dual role of HMGB1 in pancreatic cancer

Kang, R., & Tang, D. (2018) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000002 · Cited by 19

Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia

Fiñana, C., Gómez-Molina, N., Alonso-Moreno, S., & Belver, L. (2022) · Cancers · doi:10.3390/cancers14051335 · Cited by 20

Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening

Badheeb, M. A., Abdelrahim, A., Esmail, A., Umoru, G., Abboud, K., Al-Najjar, E., Rasheed, G. O., Alkhulaifawi, M., Abudayyeh, A., & Abdelrahim, M. (2022) · Current Oncology · doi:10.3390/curroncol29110686 · Cited by 20

Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective

Lam, K. K., Wong, S. H., & Cheah, P. Y. (2023) · Cells · doi:10.3390/cells12040631 · Cited by 19

New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling

Erickson, K. E., Rukhlenko, O. S., Posner, R. G., Hlavacek, W. S., & Kholodenko, B. Ν. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.008 · Cited by 21

Addressing the Right Targets in Oncology: Challenges and Alternative Approaches

Stock, J. K., Jones, N. P., Hammonds, T. R., Roffey, J., & Dillon, C. (2015) · SLAS DISCOVERY · doi:10.1177/1087057114564349 · Cited by 19

Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling

Marín‐Ramos, N. I., Piñar, C., Vázquez‐Villa, H., Martín‐Fontecha, M., González, Á., Canales, Á., Algar, S., Mayo, P. P., Jiménez‐Barbero, J., Gajate, C., et al. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201604905 · Cited by 19

Is there potential to target FOXM1 for ‘undruggable’ lung cancers?

Kalinichenko, V. V., & Kalin, T. V. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1042366 · Cited by 19

Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines

Weißbach, S., Heredia-Guerrero, S. C., Barnsteiner, S., Großhans, L., Bodem, J., Starz, H., Langer, C., Appenzeller, S., Knop, S. T., Steinbrunn, T., et al. (2020) · Cancers · doi:10.3390/cancers12020455 · Cited by 18

Polycistronic baculovirus expression of SUGT1 enables high-yield production of recombinant leucine-rich repeat proteins and protein complexes

Snead, K., Wall, V. E., Ambrose, H., Esposito, D., & Drew, M. R. (2022) · Protein Expression and Purification · doi:10.1016/j.pep.2022.106061 · Cited by 19

Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors

Ai, Q., Li, F., Zou, S., Zhang, Z., Jin, Y., Jiang, L., Chen, H., Deng, X., Peng, C., Mou, N., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161538 · Cited by 18

Seeing is believing: Ras dimers observed in live cells

Philips, M. R., & Der, C. J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511805112 · Cited by 18

Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells

Arafeh, R., Flores, K., Keren‐Paz, A., Maik-Rachline, G., Gutkind, N. E., Rosenberg, S. A., Seger, R., & Samuels, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-16558-0 · Cited by 18

The Hypervariable Region of K-Ras4B Governs Molecular Recognition and Function

Abdelkarim, H., Banerjee, A., Grudzien, P. K., Leschinsky, N., Abushaer, M., & Gaponenko, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225718 · Cited by 18

Oncogenic K-Ras4B Dimerization Enhances Downstream Mitogen-activated Protein Kinase Signaling

Muratcioğlu, S., Aydın, C., Odabasi, E., Özdemir, E. S., Firat‐Karalar, E. N., Jang, H., Tsai, C., Nussinov, R., Kavaklı, İ. H., Gürsoy, A., et al. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.01.002 · Cited by 19

KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents

Ischenko, I., Zhi, J., Hayman, M. J., & Petrenko, O. (2017) · Oncotarget · doi:10.18632/oncotarget.14929 · Cited by 17

Wild-type Kras expands and exhausts hematopoietic stem cells

Sasine, J. P., Himburg, H. A., Termini, C. M., Roos, M. M., Tran, E., Zhao, L., Kan, J., Li, M., Zhang, Y., de Barros, S. C., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98197 · Cited by 17

Rat ERK2 E320K

th, C. A. T., Cormier, K. W., Juang, Y.-C., Goldsmith, E. J., & Cobb, M. H. (2019) · Worldwide Protein Data Bank · doi:10.2210/pdb6ots/pdb · Cited by 18

Enhanced SNP-sensing using DNA-templated reactions through confined hybridization of minimal substrates (CHOMS)

Kim, K. T., & Winssinger, N. (2020) · Chemical Science · doi:10.1039/d0sc00741b · Cited by 17

pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model

Dutta, D., Ray, P., De, A., Ghosh, A., Hazra, R. S., Ghosh, P., Banerjee, S., Díaz, F. J., Upadhyay, S. P., Quadir, M., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297749 · Cited by 17

RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS

Seibold, M., Stühmer, T., Kremer, N., Mottok, A., Scholz, C. J., Schlösser, A., Leich, E., Holzgrabe, U., Brünnert, D., Barrio, S., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.223024 · Cited by 18

Nanocarrier-based targeting of metabolic pathways for endometrial cancer: Status and future perspectives

Wang, Y., Chen, S., Wang, H., & Guo, F. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115348 · Cited by 18

Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations

Jiang, Z., Huang, J., Xie, C., Li, X., Liu, L., He, J., PAN, H., Huang, L., Fan, X., Yao, X., et al. (2016) · Oncology Reports · doi:10.3892/or.2016.4770 · Cited by 17

Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies

Kato, S., Okamura, R., Sicklick, J., Daniels, G., Hong, D., Goodman, A., Weihe, E., Lee, S., Khalid, N., Collier, R., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32813 · Cited by 16

Validation of an LC–MS/MS method for the determination of sotorasib, a KRAS G12C inhibitor, in human plasma

Wong, P. S. H., Akrami, A., Houk, B. E., Vuu, I., & James, C. A. (2022) · Bioanalysis · doi:10.4155/bio-2022-0173 · Cited by 17

A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics

Ocal, O., Pashkov, V., Kollipara, R., Zolghadri, Y., Cruz, V. H., Hale, M. A., Heath, B. R., Artyukhin, A., Christie, A., Tsoulfas, P., et al. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.020933 · Cited by 21

Correlation of O2 transport on the micro and macro scale.

Honig, C. R., & Gayeski, T. E. (1982) · PubMed · Cited by 17

The potential of targeting Ras proteins in lung cancer

McCormick, F. P. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.1000304 · Cited by 17

Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer

Chuang, H.-C., Huang, P.-H., Kulp, S. K., & Chen, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.006 · Cited by 16

Quantification of ERK Kinase Activity in Biological Samples Using Differential Sensing

Zamora‐Olivares, D., Kaoud, T. S., Zeng, L., Pridgen, J. R., Zhuang, D. L., Ekpo, Y. E., Nye, J. R., Telles, M., Anslyn, E. V., & Dalby, K. N. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00580 · Cited by 16

The discovery and maturation of peptide biologics targeting the small G-protein Cdc42: A bioblockade for Ras-driven signaling

Tetley, G. J. N., Murphy, N. P., Bonetto, S., Ivanova, G. D., Revell, J. D., Mott, H. R., Cooley, R., & Owen, D. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010077 · Cited by 16

Influence of Cholesterol on the Orientation of the Farnesylated GTP-Bound KRas-4B Binding with Anionic Model Membranes

Lu, H., & Martı́, J. (2020) · Membranes · doi:10.3390/membranes10110364 · Cited by 13

Monoallelic Loss of the Imprinted Gene Grb10 Promotes Tumor Formation in Irradiated Nf1+/- Mice

Mroue, R. M., Huang, B. Z., Braunstein, S. E., Firestone, A. J., & Nakamura, J. L. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005235 · Cited by 16

Patterning of Oncogenic Ras Clustering in Live Cells Using Vertically Aligned Nanostructure Arrays

Mu, H., Zeng, Y., Zhuang, Y., Gao, W., Zhou, Y., Rajalingam, K., & Zhao, W. (2022) · Nano Letters · doi:10.1021/acs.nanolett.1c03886 · Cited by 15

T cells discriminate between groups C1 and C2 HLA-C

Sim, M. J. W., Stotz, Z., Lu, J., Brennan, P., Long, E. O., & Sun, P. D. (2022) · eLife · doi:10.7554/elife.75670 · Cited by 16

Oncogenic RAS-induced downregulation of ATG12 is required for survival of malignant intestinal epithelial cells

Yoo, B. H., Khan, I. A., Koomson, A., Gowda, P. S., Sasazuki, T., Shirasawa, S., Gujar, S. A., & Rosen, K. V. (2017) · Autophagy · doi:10.1080/15548627.2017.1370171 · Cited by 16

New weapons to penetrate the armor: Novel reagents and assays developed at the NCI RAS Initiative to enable discovery of RAS therapeutics

Esposito, D., Stephen, A. G., Turbyville, T. J., & Holderfield, M. T. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.006 · Cited by 16

Anionic Lipids Impact RAS-Binding Site Accessibility and Membrane Binding Affinity of CRAF RBD-CRD

Travers, T. S., López, C. A., Agamasu, C., Hettige, J. J., Messing, S. A. J., Garcı́a, A. E., Stephen, A. G., & Gnanakaran, S. (2020) · Biophysical Journal · doi:10.1016/j.bpj.2020.06.021 · Cited by 16

KRAS mutation‐independent downregulation of MAPK/PI3K signaling in colorectal cancer

Lam, K. K., Tang, C. L., Tan, E., Wong, S. H., & Cheah, P. Y. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13163 · Cited by 16

Oncogenic Kras-Mediated Cytokine CCL15 Regulates Pancreatic Cancer Cell Migration and Invasion through ROS

Messex, J. K., Adams, K. L., Hawkins, W. G., DeNardo, D. G., Bardeesy, N. M., Billadeau, D. D., & Liou, G. (2022) · Cancers · doi:10.3390/cancers14092153 · Cited by 15

Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia

Chen, Y., Yin, Z., Westover, K. D., Zhou, Z., & Shu, L. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0504 · Cited by 15

Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report

Metro, G., Valtorta, E., Siggillino, A., Lauricella, C., Cenci, M., Ludovini, V., Minenza, E., Prosperi, E., Ricciuti, B., Rebonato, A., et al. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.559 · Cited by 16

Latest Advances Towards Ras Inhibition: A Medicinal Chemistry Perspective

Sautier, B., Nising, C. F., & Wortmann, L. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608270 · Cited by 15

Rationale for RAS Mutation-Tailored Therapies

Montalvo, S. K., Li, L., & Westover, K. D. (2016) · Future Oncology · doi:10.2217/fon-2016-0363 · Cited by 15

Chromosome 19q13 disruption alters expressions of CYP2A7, MIA and MIA-RAB4B lncRNA and contributes to FAP-like phenotype in APC mutation-negative familial colorectal cancer patients

Thean, L. F., Wong, Y. H., Lo, M., Loi, C. T., Chew, M. H., Tang, C. L., & Cheah, P. Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173772 · Cited by 15

Identification of Serine 119 as an Effective Inhibitor Binding Site of M. tuberculosis Ubiquitin-like Protein Ligase PafA Using Purified Proteins and M. smegmatis

Jiang, H., Czajkowsky, D. M., Wang, T., Wang, X., Wang, J., Zhang, H., Liu, C., Wu, F., He, X., Xu, Z., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.03.025 · Cited by 19

Proceedings of the fifth international RASopathies symposium: When development and cancer intersect

Rauen, K. A., Schoyer, L., Schill, L., Stronach, B. E., Albeck, J. G., Andresen, B. S., Cavé, H., Ellis, M., Fruchtman, S. M., Gelb, B. D., et al. (2018) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.40632 · Cited by 15

CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma

Alon, M., Arafeh, R., Lee, J. S., Madan, S., Kalaora, S., Nagler, A., Abgarian, T., Greenberg, P., Ruppin, E., & Samuels, Y. (2018) · Oncotarget · doi:10.18632/oncotarget.25805 · Cited by 15

NMR in integrated biophysical drug discovery for RAS: past, present, and future

Marshall, C. B., KleinJan, F., Gebregiworgis, T., Lee, K., Fang, Z., Eves, B. J., Liu, N. F., Gasmi-Seabrook, G. M. C., Enomoto, M., & Ikura, M. (2020) · Journal of Biomolecular NMR · doi:10.1007/s10858-020-00338-6 · Cited by 15

TRIM58 is a Prognostic Biomarker Remodeling the Tumor Microenvironment in KRAS -Driven Lung Adenocarcinoma

Chen, X., Wang, Y., Qu, X. H., Bie, F., Wang, Y., & Du, J. (2021) · Future Oncology · doi:10.2217/fon-2020-0645 · Cited by 16

Targeting Ras with MacromoleculesPreprint

Pei, D., Chen, K., & Liao, H. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031476 · Cited by 15

Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families

Li, L., Meyer, C., Zhou, Z.-W., Elmezayen, A., & Westover, K. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167626 · Cited by 14

Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer

Ruan, H., Leibowitz, B. J., Peng, Y., Shen, L., Chen, L., Kuang, C., Schoen, R. E., Lu, X., Zhang, L., & Yu, J. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00070-7 · Cited by 14

KRAS Inhibitor that Simultaneously Inhibits Nucleotide Exchange Activity and Effector Engagement

Pagba, C. V., Gupta, A. K., Naji, A. K., van der Hoeven, D., Churion, K. A., Liang, X., Jakubec, J. L., Höök, M., Zuo, Y., de Kraatz, M. M., et al. (2022) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.2c00045 · Cited by 14

Integrating isothermal amplification techniques and LNA-based AI-assisted electrochemical bioassay for analysis of KRAS G12V point mutation

Sebuyoya, R., Sevcikova, S., Yusuf, B., & Bartošík, M. (2025) · Talanta · doi:10.1016/j.talanta.2025.127709 · Cited by 14

Intracellular NF-HEV/IL-33 harbors essential roles in Ras-induced cellular transformation by contributing to cyclin D1 protein synthesis

Ohta, S., Tago, K., Funakoshi‐Tago, M., Matsugi, J., & Yanagisawa, K. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.04.013 · Cited by 14

Novel Targets in Pancreatic Cancer Therapy - Current Status and Ongoing Translational Efforts

Bisht, S., & Feldmann, G. (2018) · Oncology Research and Treatment · doi:10.1159/000493437 · Cited by 14

Two Distinct Structures of Membrane‐Associated Homodimers of GTP‐ and GDP‐Bound KRAS4B Revealed by Paramagnetic Relaxation Enhancement

Lee, K., Fang, Z., Enomoto, M., Gasmi-Seabrook, G. M. C., Zheng, L., Koide, S., Ikura, M., & Marshall, C. B. (2020) · Angewandte Chemie · doi:10.1002/ange.202001758 · Cited by 15

Small Molecule APY606 Displays Extensive Antitumor Activity in Pancreatic Cancer via Impairing Ras-MAPK Signaling

Guo, N., Liu, Z., Zhao, W., Wang, E., & Wang, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155874 · Cited by 14

Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 Cells

Waters, A. M., Bagni, R., Portugal, F. H., & Hartley, J. L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163272 · Cited by 14

All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic cancer driven by mutant KRAS

Vallejo, A., Valencia, K., & Vicent, S. (2017) · Molecular & Cellular Oncology · doi:10.1080/23723556.2017.1314239 · Cited by 14

Modeling of RAS complexes supports roles in cancer for less studied partners

Engin, H. B., Carlin, D. E., Pratt, D. R., & Carter, H. K. (2017) · BMC Biophysics · doi:10.1186/s13628-017-0037-6 · Cited by 14

A mechanism for the response of KRASG13D expressing colorectal cancers to EGFR inhibitors

McFall, T. B., & Stites, E. C. (2020) · Molecular & Cellular Oncology · doi:10.1080/23723556.2019.1701914 · Cited by 15

Haspin regulates Ras localization to promote Cdc24-driven mitotic depolarization

Quadri, R., Galli, M. G., Galati, E., Rotondo, G., Gallo, G. R., Panigada, D., Plevani, P., & Muzi-Falconi, M. (2020) · Cell Discovery · doi:10.1038/s41421-020-0170-2 · Cited by 14

Defeat mutant KRAS with synthetic lethality

Pang, X., & Liu, M. (2016) · Small GTPases · doi:10.1080/21541248.2016.1213783 · Cited by 14

Pan-cancer analysis to character the clinicopathological and genomic features of KRAS-mutated patients in China

Wu, L., Rao, W., Guo, L., Zhang, F., Li, W., & Ying, J. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06118-9 · Cited by 13

Autopromotion of K-Ras4B Feedback Activation Through an SOS-Mediated Long-Range Allosteric Effect

He, X., Du, K., Wang, Y., Fan, J., Li, M., Ni, D., Lu, S., Bian, X., & Liu, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.860962 · Cited by 13

Characterisation of a cyclic peptide that binds to the RAS binding domain of phosphoinositide 3-kinase p110α

Ismail, M., Martin, S. R., George, R., Houghton, F., Kelly, G. P., Chaleil, R. A. G., Anastasiou, P., Wang, X., O’Reilly, N., Federico, S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-28756-0 · Cited by 15

Genomic landscape of gallbladder cancer: insights from whole exome sequencing

Awasthi, S., Kumar, R., Pradhan, D., Rawal, N., Goel, H., Sahu, P., Sisodiya, S., Rana, R., Kumar, S., Dash, N. R., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000002031 · Cited by 14

Opposite feedback from mTORC1 to H-ras and K-ras4B downstream of SREBP1

Posada, I. M. D., Lectez, B. L. P., Siddiqui, F. A., Oetken-Lindholm, C., Sharma, M., & Abankwa, D. (2017) · Scientific Reports · doi:10.1038/s41598-017-09387-8 · Cited by 13

Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 17

Mund, J. A., Park, S.-J., Smith, A. E., He, Y., Jiang, L., Hawley, E., Roberson, M. J., Mitchell, D. K., Abu-Sultanah, M., Yuan, J., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010981 · Cited by 14

Diclofenac Enhances Docosahexaenoic Acid-Induced Apoptosis in Vitro in Lung Cancer Cells

Poku, R. A., Jones, K. J., Baren, M. V., Alan, J. K., & Amissah, F. (2020) · Cancers · doi:10.3390/cancers12092683 · Cited by 13

FLIM-FRET Analysis of Ras Nanoclustering and Membrane-Anchorage

Parkkola, H., Siddiqui, F. A., Oetken-Lindholm, C., & Abankwa, D. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1190-6_13 · Cited by 13

MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer

Fanini, F., Bandini, E., Plousiou, M., Carloni, S., Wise, P. M., Neviani, P., Murtadha, M., Foca, F., Fabbri, F., Vannini, I., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413357 · Cited by 13

AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis

Kim, D. G., Choi, Y., Lee, Y., Lim, S., Kong, J., Song, J., Roh, Y., Harmalkar, D. S., Lee, K., Goo, J.-I., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30149-2 · Cited by 13

Inferring pathway dysregulation in cancers from multiple types of omic data

MacNeil, S. M., Johnson, W. E., Li, D. Y., Piccolo, S., & Bild, A. H. (2015) · Genome Medicine · doi:10.1186/s13073-015-0189-4 · Cited by 13

In-vivo detection of binary PKA network interactions upon activation of endogenous GPCRs

Röck, R., Bachmann, V. A., Bhang, H.-E. C., Malleshaiah, M. K., Raffeiner, P., Mayrhofer, J. E., Tschaikner, P., Bister, K., Aanstad, P., Pomper, M. G., et al. (2015) · Scientific Reports · doi:10.1038/srep11133 · Cited by 13

Drugging the undruggable RAS: Mission Possible?

Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997

Ras and Ras Signaling as a Therapeutic Target in Cancer

Sliker, B. H., & Campbell, P. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00006-2

Targeting the “undruggable” RAS with biologics

Whaby, M., Khan, I., & O’Bryan, J. P. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.006 · Cited by 19

Targeting the Undruggable: Small Molecule Modulation of Ras Proteins

Kim, J. (2025) · International journal of high school research · doi:10.36838/v7i9.103

RASpecting the oncogene: New pathways to therapeutic advances

Stout, M. C., & Campbell, P. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.10.022 · Cited by 7